These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20009971)

  • 41. Subcutaneous phaeohyphomycosis in a renal transplant recipient successfully treated with voriconazole.
    Larsen CG; Arendrup MC; Krarup E; Pedersen M; Thybo S; Larsen FG
    Acta Derm Venereol; 2009 Nov; 89(6):657-8. PubMed ID: 19997708
    [No Abstract]   [Full Text] [Related]  

  • 42. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients.
    Veroux M; Corona D; Gagliano M; Sorbello M; Macarone M; Cutuli M; Giuffrida G; Morello G; Paratore A; Veroux P
    Transplant Proc; 2007; 39(6):1838-40. PubMed ID: 17692627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of voriconazole in the treatment of central nervous system blastomycosis.
    Ta M; Flowers SA; Rogers PD
    Ann Pharmacother; 2009 Oct; 43(10):1696-700. PubMed ID: 19724015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Voriconazole-associated phototoxicity.
    Riahi RR; Cohen PR
    Dermatol Online J; 2011 Feb; 17(2):15. PubMed ID: 21382298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aspergillus fumigatus spondylodiskitis in renal transplant patient: voriconazole experience.
    Ersoy A; Dizdar OS; Koc AO; Akalin H; Ener B
    Exp Clin Transplant; 2011 Aug; 9(4):265-9. PubMed ID: 21819372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical efficacy of new antifungal agents.
    Kauffman CA
    Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A case of orbital apex syndrome caused by localized invasive aspergillosis successfully treated with voriconazole].
    Kuga A; Oishi K; Ishida H; Kanda F
    Rinsho Shinkeigaku; 2007 May; 47(5):207-10. PubMed ID: 17585601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
    Siwek GT; Dodgson KJ; de Magalhaes-Silverman M; Bartelt LA; Kilborn SB; Hoth PL; Diekema DJ; Pfaller MA
    Clin Infect Dis; 2004 Aug; 39(4):584-7. PubMed ID: 15356827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. X-linked chronic granulomatous disease with voriconazole-induced photosensitivity/ photoaging reaction.
    Frisch S; Askari SK; Beaty SR; Burkemper CN
    J Drugs Dermatol; 2010 May; 9(5):562-4. PubMed ID: 20480802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
    Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
    Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis.
    Jain LR; Denning DW
    J Infect; 2006 May; 52(5):e133-7. PubMed ID: 16427702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
    Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
    Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Voriconazole-induced pancreatitis in a patient of acute myeloid leukemia and invasive aspergillosis.
    Philip A; Sivaprakasam P; Sagar TG; Ganesan P
    J Pediatr Hematol Oncol; 2012 Jul; 34(5):406. PubMed ID: 22713708
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
    Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
    Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pseudoporphyria associated with voriconazole.
    Kwong WT; Hsu S
    J Drugs Dermatol; 2007 Oct; 6(10):1042-4. PubMed ID: 17966183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.
    Denning DW; Griffiths CE
    Clin Exp Dermatol; 2001 Nov; 26(8):648-53. PubMed ID: 11722447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Successful treatment by voliconazole for pulmonary and adductor magnus muscle aspergillosis induced by immunosuppressive therapy for hypersensitivity pneumonia].
    Ichiyasu H; Yamamura A; Honda M; Okamoto S; Tsumori K; Okamoto T; Sato K; Matsumoto M; Kohrogi H
    Nihon Kokyuki Gakkai Zasshi; 2006 Oct; 44(10):754-60. PubMed ID: 17087345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Porphyria cutanea tarda revealed by voriconazole].
    Hickman G; Duval A; Picard C; Petit A
    Ann Dermatol Venereol; 2010 Jan; 137(1):36-9. PubMed ID: 20110066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Voriconazole-associated severe hyponatremia.
    Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
    Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.